• Users Online: 135
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE - CARDIOLOGY IN REVIEW
Year : 2015  |  Volume : 1  |  Issue : 3  |  Page : 244-246

Cardiology in review: 2015


Department of Cardiology, CNC, AIIMS, New Delhi, India

Correspondence Address:
Sunil Kumar Verma
Department of Cardiology, CNC, AIIMS, Suite No. 24, 7th Floor, Ansari Nagar, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2395-5414.177233

Rights and Permissions

In 2015, the SPRINT Research Group showed the advantage of intensively controlling systemic blood pressure. Are the leads of pacemaker going to be their vestigial remnant? - A rapidly advancing technology is showing success with Micra and Nanostim. Similarly, ABSORB III showed favorable results for bioresorbable scaffolds for noncomplex coronary lesions. Once again, the trial of routine aspiration thrombectomy with percutaneous coronary intervention (PCI) versus PCI alone in patients with ST-elevation myocardial infarction (STEMI) trial failed to show the benefit of manual thrombus aspiration in acute STEMI. The Food and Drug Administration (FDA) Class 1 recalled rotawires because wire fracture affected rotablation. Proton pump inhibitors demonstrated reduction in the gastrointestinal bleeding in postmyocardial infarction patients on antithrombotics and concomitant nonsteroidal anti-inflammatory drugs use. The antidotes for newer oral anticoagulants are significant achievements of this year (REVERSE AD, ANNEXA-A, and ANNEXA-R). The FDA approval of proprotein convertase subtilisin-Kexin type 9 drugs for cholesterol lowering is a remarkable development. Selexipag is now approved for treatment of pulmonary hypertension. Different approaches of atrial fibrillation ablation were compared in substrate and trigger ablation for reduction of atrial fibrillation trail part II. High-sensitivity cardiac troponin I assays are a new hope for decision making in suspected acute coronary syndrome.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1647    
    Printed26    
    Emailed0    
    PDF Downloaded127    
    Comments [Add]    

Recommend this journal